CLINICAL_TRIALS
trial_result
· 2020-03-04
Clinical Trial Update: Carfilzomib in Refractory Renal Cell Carcinoma (RCC) [Phase 2]
Summary
Phase 2 clinical trial update for carfilzomib in refractory renal cell carcinoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-04